Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

By J. Cohen, A. Coles, Douglas L Arnold, Christian Confavreux, E. Fox, H. Hartung, E. Havrdová, Krzysztof W Selmaj, Howard L. Weiner, Elizabeth Fisher and 8 more. The Lancet, 2012

1,172 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/3196ed03a58b3d873d079e3c5d34290c3d755857